McKesson
MCK NYSE· Health Care Distributors
Last close · Oct 26, 2026
$992.87
KIRA · Stoqly’s AI analyst, in plain words
- McKesson had $403.4B of revenue in fiscal 2026, up 12.4% on the year before. Over five years, revenue changed +11.1% a year on average.
- Its operating margin was 1.5%, up 0.3 pts: of every 100 in sales, about 2 is left after running the business.
- McKesson made $4.8B of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 6.0% a year.
- Free cash flow was $5.7B in fiscal 2026, 1.4% of revenue.
- McKesson returned $5.1B to shareholders in fiscal 2026, 90% of free cash flow. The diluted share count fell 3.1%.
- McKesson owes $2.7B more than it holds in cash, about 0.4 years of operating profit.
Market cap
$118.4B
P/E
26.6x
Revenue
$403.4B
Net income
$4.8B
Free cash flow
$5.7B
Operating margin
1.5%
McKesson in 30 seconds · fiscal 2026
Are sales growing?
+12.4%
Yes. Sales grew 12.4% last year.
Does it make a profit?
1.2%
A little. It keeps 1.2% of every sale as profit.
Does profit turn into cash?
1.4%
Partly. 1.4% of sales ends up as free cash.
Is debt under control?
0.4x
Yes. It could repay its debt with 0.4 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
26.6x
One share costs 26.6 times its yearly profit per share. Typical for its sector: 28.4x.
What McKesson does
McKesson is a healthcare distribution and services company whose business roots go back to 1833. Its fiscal year runs from April 1 to March 31. It supplies drugs, medical products and services to drugstores, hospitals, physician practices, care providers and drug makers. Since the second quarter of fiscal 2026 it reports four segments. North American Pharmaceutical distributes branded, generic, specialty, biosimilar and over-the-counter drugs and other health products to customers in the United States and Canada, and sells software and consulting services to pharmacies. Oncology & Multispecialty provides specialty drug distribution, group purchasing, infusion services and technology to cancer and other specialty practices, and supports the U.S. Oncology Network of physician-led cancer practices. Prescription Technology Solutions offers tools that help patients get and afford medicine, such as electronic prior authorization and patient enrollment.
Biggest risks, in its own words
- Costly legal disputes and government actions over its role in distributing controlled substances.
- Extensive and changing healthcare, fraud and abuse and environmental laws.
- Possibly losing its ability to buy, store or distribute drugs, including controlled substances.
- The planned separation of Medical-Surgical Solutions may not be completed on current terms or timing.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 8, 2026
- Legal name
- McKESSON CORPORATION
- CIK
- 0000927653
McKesson · MCK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $264.0B | $276.7B | $309.0B | $359.1B | $403.4B |
| Revenue growth | 10.8% | 4.8% | 11.7% | 16.2% | 12.4% |
| Gross margin | 5.0% | 4.5% | 4.2% | 3.7% | 3.6% |
| Operating margin | 0.8% | 1.6% | 1.3% | 1.2% | 1.5% |
| Net income | $1.1B | $3.6B | $3.0B | $3.3B | $4.8B |
| Net margin | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
| Diluted EPS | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
| Cash | |||||
| Cash from operations | $4.4B | $5.2B | $4.3B | $6.1B | $6.2B |
| Capital expenditure | $388M | $390M | $431M | $537M | $436M |
| Free cash flow | $4.0B | $4.8B | $3.9B | $5.5B | $5.7B |
| FCF margin | 1.5% | 1.7% | 1.3% | 1.6% | 1.4% |
| Dividends paid | $277M | $292M | $314M | $345M | $381M |
| Share buybacks | $3.5B | $3.6B | $3.0B | $3.1B | $4.8B |
| Share count change | −4.1% | −7.7% | −5.7% | −4.5% | −3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $3.5B | $4.7B | $4.6B | $5.7B | $4.0B |
| Debt incl. finance leases | $6.1B | $5.8B | $5.8B | $5.8B | $6.7B |
| Shareholders' equity | −$2.3B | −$1.9B | −$2.0B | −$2.1B | −$2.2B |
| Net debt / EBITDA | 1.1x | 0.2x | 0.3x | 0.0x | 0.4x |
| Current ratio | 1.0x | 0.9x | 0.9x | 0.9x | 0.9x |
| Interest coverage | 11.5x | 17.7x | 15.5x | 16.7x | 25.2x |
| Returns and quality | |||||
| Piotroski F-score | 7 | 7 | 6 | 7 | 6 |
| Altman Z'' | 0.4 | 0.7 | 0.7 | 0.6 | 0.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$29.1M
8 insiders
Of sales under plans
98%
$28.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
McKesson · MCK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| McKesson MCK | $118.4B | 12.4% | 1.5% | 1.4% | — | 26.6x | 6 |
| Cencora COR | $64.0B | 9.3% | 0.8% | 1.0% | — | 24.5x | 7 |
| Cardinal Health CAH | $59.6B | 14.2% | 1.0% | 1.8% | — | — | 6 |
| Henry Schein HSIC | $9.7B | 4.0% | 5.0% | 4.4% | 7.5% | 24.6x | 6 |
| CVS Health CVS | $119.1B | 7.9% | 1.2% | 1.9% | 2.9% | 24.4x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $992.87 a share, the company is worth $118.4B: 26.6 times its earnings of the last four quarters.
McKesson grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 3 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000927653). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.